PrEP – SONNTAG
VARIOUS STAIN COLOURS (MAY NOT BE THE COLOUR IN THE PRODUCT PHOTO)
SONNTAG/ MEDIUM CONCAVE
9.125″ x 31.5″ / NOSE: 6.32″/ WHEEL BASE: 14.38″ / TAIL: 6.68″
PrEP IS AN UNDERSTANDABLY LOADED CONVERSATION IN THE QUEER COMMUNITY. SO FAR THE PRIVILEGED WHITE CIS WESTERN HEMISPHERE HAS BEEN GRANTED ACCESS TO IT GRADUALLY. WHILE IT SAVES COUNTLESS PRECIOUS LIVES, IT ALSO PERPETUATES NON COMMUNICATION BETWEEN LOVERS AND PARTNERS ALIKE. THE OLD “DON’T ASK DON’T TELL” RULE PERVADES. FOR POLY FOLKS THIS SHOULD BE A RED FLAG TO TAKE TO HEART. NOW WHEN ONE IS ABOUT TO MAKE AN IMPULSIVE DECISION IN THE HEAT OF TE MOMENT, THERE IS ANOTHER BARRIER TO NOT CONTRACT THE HIV VIRUS. BEING IN CONTACT WITH REST OF THE STI SPECTRUM IS STILL A ROLL OF THE DICE TO BE CONSIDERED. THE DEEP ROOTED HISTORICAL SHAME ATTACHED TO BODIES WHO HAVE QUEER SEX IS LESSENING SLOWLY YEAR AFTER YEAR WITH MUCH HEAVY LIFTING. GETTING REGULARLY TETSED AND PRACTICING RADICAL CONSENT IS THE BASELINE FOR INFORMING YOURSELF AND YOUR LOVERS. IT IS IMPERATIVE TO MEET YOUR OWN NEEDS FIRST AND TAKE THE TIME TO SEPARATE THE MAGNETS. SOME FOLKS CAN’T DIGEST THAT MAGIC BLUE PILL, MY BODY STRUGGLES WITH IT. PrEP IS BECOMING A TOOL FOR HARM REDUCTION IN THE QUEER COMMUNITY.
Pre-exposure prophylaxis (PrEP) is the use of medications used to prevent the spread of disease in people who have not yet been exposed to a disease-causing agent, usually a virus. The term typically refers to the specific use of antiviral drugs as a strategy for HIV/AIDS prevention. PrEP is one of a number of HIV prevention strategies for people who are HIV negative but who also have a higher risk of acquiring HIV, including sexually active adults at increased risk of HIV, people who engage in injection drug use (see drug injection), and serodiscordant sexually active couples.
When used as directed, PrEP has been shown to be highly effective, reducing the risk of acquiring HIV up to 99%. As of 2019, the World Health Organization (WHO) recommends two drug combinations for the use as PrEP for HIV/AIDS: the combination of tenofovir disoproxil and emtricitabine (Truvada), or the combination of tenofovir disoproxil and lamivudine (Cimduo). In October 2019, the U.S. Food and Drug Administration (FDA) approved the combination of emtricitabine and tenofovir alafenamide (Descovy) to be used as PrEP in addition to Truvada, which provides similar levels of protection.